Filtered By:
Condition: Heart Failure
Therapy: Dialysis
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 251 results found since Jan 2013.
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research
Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease
Conclusion: The cohort study found that in real world practice, among patients with
advanced CKD stage V, use of sodium bicarbonate was associated with similar risk of
dialysis compared with non-users, Nonetheless, use of sodium bicarbonate was
associated with significantly lower rate of MACE and mortality. The study results
reinforced the benefits of sodium bicarbonate therapy in the expanding CKD
population. Further prospective studies are needed to confirm these findings.
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research
Association of intradialytic hypertension with future cardiovascular events and mortality in hemodialysis patients: effects of ambulatory blood pressure
CONCLUSIONS: IDHTN patients had higher risk for mortality and cardiovascular outcomes but this risk is at least partly confounded by the elevated BP levels during the interdialytic period.PMID:37302385 | DOI:10.1159/000531477
Source: American Journal of Nephrology - June 11, 2023 Category: Urology & Nephrology Authors: Fotini Iatridi Marieta P Theodorakopoulou Antonios Karpetas Vasiliki Sgouropoulou Areti Georgiou Eleni Karkamani Artemios Karagiannidis Aikaterini Papagianni Pantelis A Sarafidis Source Type: research
Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
ConclusionGlobally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.
Source: Advances in Therapy - July 26, 2023 Category: Drugs & Pharmacology Source Type: research
